Senesco Technologies, Inc. (SNT) Release: Combination of Lenalidomide and SNS01-T Effective in Cancer Model

5/1/2012 10:55:53 AM

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE AMEX: SNT) announced today that a high level of tumor eradication in a mouse model of human multiple myeloma was achieved with a combination of SNS01-T and lenalidomide.

Read at BioSpace.com

Read Article at

Related Companies

News Categories

• BioSpace.com

• Senesco Technologies, Inc.

• Clinical - Pre-Clinical